Stockscreener 앱 받기
2.19
4.78%
0.10
시간 외 거래:
2.25
0.06
+2.74%
전일 마감가:
$2.09
열려 있는:
$2.22
하루 거래량:
567.57K
Relative Volume:
2.79
시가총액:
$63.15M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-2.3804
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
+4.29%
1개월 성능:
+0.00%
6개월 성능:
+12.31%
1년 성능:
+23.73%
1일 변동 폭
$2.09
$2.2533
1주일 범위
$1.94
$2.2533
52주 변동 폭
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.19 | 68.27M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Does Immix Biopharma Inc have consistent dividend growthWeekly Profit Analysis & Smart Swing Trading Alerts - khodrobank.com
Using economic indicators to assess Immix Biopharma Inc. potentialMarket Performance Recap & Risk Controlled Swing Trade Alerts - newser.com
What does recent volatility data suggest for Immix Biopharma Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Daily Brief Health Care: Vivani Medical, Medcaptain Medical Technology, Dr Lal PathLabs Ltd, Immix Biopharma Inc, MDxHealth SA, Oncology Institute and more - Smartkarma
Will a bounce in Immix Biopharma Inc. offer an exit2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Measuring Immix Biopharma Inc.’s beta against major indices2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Heatmap analysis for Immix Biopharma Inc. and competitorsJuly 2025 Institutional & Long-Term Investment Growth Plans - newser.com
Immix Biopharma — NEXICART-2 enrolment progressing well - Smartkarma
Market Rankings: Is Immix Biopharma Inc benefiting from innovation trends2025 Valuation Update & Technical Confirmation Trade Alerts - khodrobank.com
Immix Biopharma surpasses 50% enrollment milestone in AL amyloidosis trial - Investing.com India
Immix Biopharma says that 50% enrollment has already been surpassed in NEXICART-2 - MarketScreener
Regression analysis insights on Immix Biopharma Inc. performanceBond Market & Comprehensive Market Scan Insights - newser.com
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 - Investing News Network
Immix Biopharma Surpasses 50% Enrollment Milestone in NEXICART-2 Clinical Trial for AL Amyloidosis, Paving the Way for FDA BLA Submission - Quiver Quantitative
Immix Biopharma Announces 50% Enrollment Milestone - GlobeNewswire
First Potential FDA-Approved CAR-T Therapy: ImmixBio's AL Amyloidosis Trial Hits Major Milestone - Stock Titan
Has Immix Biopharma Inc. found a price floorSwing Trade & Proven Capital Preservation Tips - newser.com
Wall Street Recap: How liquid is Immix Biopharma Inc. stockMarket Growth Summary & Technical Buy Zone Confirmation - khodrobank.com
MACD Signal: Can Amalgamated Financial Corp stock double in the next year2025 Winners & Losers & Short-Term Swing Trade Alerts - khodrobank.com
Hunton Represents Goose Capital in Immix Biopharma Investment - Hunton Andrews Kurth LLP
Resistance Check: Does Immix Biopharma Inc have consistent dividend growth2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - khodrobank.com
Insider Buying: Ilya Rachman Acquires Additional Shares of Immix Biopharma Inc (IMMX) - GuruFocus
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Immix Biopharma Inc. stock momentum explainedMarket Growth Report & Technical Analysis for Trade Confirmation - newser.com
Analyzing Immix Biopharma Inc. with multi timeframe chartsSell Signal & AI Powered Market Entry Strategies - newser.com
Stock Recap: Is INDV gaining market shareMarket Sentiment Summary & AI Driven Stock Price Forecasts - خودرو بانک
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
Aug Spikes: Can Immix Biopharma Inc. stock outperform in a bear marketShort Setup & Smart Investment Allocation Insights - khodrobank.com
Buy Signal: Is Immix Biopharma Inc in a bullish channelJuly 2025 Decliners & Target Return Focused Stock Picks - khodrobank.com
Market Recap: Can Immix Biopharma Inc. grow without external fundingPrice Action & Daily Chart Pattern Signals - خودرو بانک
Does Immix Biopharma Inc. qualify in momentum factor screeningJuly 2025 Gainers & Free Reliable Trade Execution Plans - newser.com
Retail Surge: Can XYZG expand into new marketsJuly 2025 PostEarnings & Stepwise Trade Signal Guides - خودرو بانک
Market Catalysts: Is Immix Biopharma Inc benefiting from innovation trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - khodrobank.com
Earnings Recap: How cyclical is Immix Biopharma Inc.’s revenue stream2025 EndofYear Setup & High Accuracy Investment Signals - خودرو بانک
Will Immix Biopharma Inc. rebound enough to break even2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
S P Trends: Is Immix Biopharma Inc. stock a good dividend stockWeekly Risk Report & Proven Capital Preservation Methods - khodrobank.com
HC Wainwright Forecasts Strong Price Appreciation for Immix Biopharma (NASDAQ:IMMX) Stock - Defense World
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
1.43%
0.09%
자본화:
|
볼륨(24시간):